Individual Study / EPIC-Potsdam

European Prospective Investigation into Cancer and Nutrition (Potsdam)
  1. Home
  2. Individual Studies
  3. EPIC-Potsdam

European Prospective Investigation into Cancer and Nutrition (Potsdam)

EPIC-Potsdam logo
Networks -
Datasets -
Variables -
Start Year
1994
Funding
EU, German Cancer Aid, BMBF, State of Brandenburg
Visit EPIC-Potsdam
Add to cart

Members

Download
Investigators Contacts
  • Prof. Dr. Matthias Schulze
    Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke
  • Prof. Dr. Matthias Schulze
    Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke

Design

Study design
Cohort
Follow Up
yes, ongoing, 20 years

Marker Paper

DOI:10.1159/000012786 DOI:10.1159/000012787

PUBMED 10592368

Recruitment

Sources of Recruitment
  • Individuals

Number of participants

Number of participants
27,548
Number of participants with biosamples
Supplementary Information
10904 M 16644 F

Timeline

EPIC-Potsdam

Selection Criteria
Minimum age
35
Maximum age
65
Newborns
Twins
Countries
  • Germany
International/National/Regional (region name)
Brandenburg
Ethnic Origin
Health Status

Recruitment

Sources of recruitment
  • General population

Number of participants

Number of participants
27,548
Number of participants with biosamples
Supplementary Information
Data Collection Event
Start Date
2014
End Date
2020

Measurements & methods

Dietary intake

yes/no
  • Information collected on habitual food intake collected
  • Special dietary aspects collected (e.g. supplements, probiotics, prebiotics and synbiotics)
Methods
  • 24-hour dietary recall
  • FFQ
24-hour dietary recall
Administration method
Face-to-face interview
FFQ
Type of questionnaire
Semi-quantitative
Administration method
Self-reported
Administration type
Web/computer-based
Reference period
Year

Anthropometric measurements

Weight/height
Measured
Waist/hip circumference
Measured

Sociodemographic information

Information collected
Sex, age, residence, education, etc.
Questionnaire name/set of questions
Questionnaire name/set of questions
Administration method
Self-reported

Medication

Information collected
Drug dosage and drug name
Antibiotics
Last treatment and frequency collected

Health status

Information collected
Various
Measurements
Various

Biological samples and laboratory measurements

Samples collected
Blood, urine, feces, hair

Biomarkers

Lipids

Measurement(s)
Various
Medium
Plasma, serum

Glucose

Measurement(s)
Various
Medium
Plasma, serum, RBC

Inflammation markers

Measurement(s)
Various
Medium
Plasma

Adiposity biomarkers

Measurement(s)
Various
Medium
Plasma

Other biomarkers

Measurement(s)
Various
Medium
Plasma, serum

Microbiome

Microbial material
16S rDNA (V3-V4 region)
Number of samples/number of individuals
3,299
Library source and library selection
Metabarcoding
Medium/tissue
Feces
Sampling collection method
Invitek tubes with DNA stabilizer (collected at home by participants)
Sequencing platform
Illumina MiSeq v3
Read length/depth
2x300bp/~20,000 reads
Further details
16S amplicon sequenced
Information on type of meal last eaten prior to sample extraction available
no